If you’ve spent a lot of time outdoors in New England, you’ve likely crossed paths with, and probably stepped on, lichens.

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” ...

The post Lipella Reports Additional Positive Data from Phase 2a Trial of LP-310 in Oral Lichen Planus appeared first on PRISM MarketView.

Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral RinsePhase 2a Study Now Fully Enrolled ...

Lipella Pharmaceuticals (LIPO) announced topline results from the second cohort of its Phase 2a multicenter, dose-ranging trial evaluating ...

Lipella Pharmaceuticals chief medical officer and co-founder Dr Michael Chancellor said: “The completion of enrollment in our ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the ...

“The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no FDA ...